•
KZ
KZIA
Kazia Therapeutics Limited American Depositary Shares
polygonPHARMACEUTICAL PREPARATIONS
--
Price Chart
Market Cap
80.26M
Volume
9.46K
52W High
$17.40
52W Low
$2.86
Open
$7.14
Prev Close
$7.08
Day Range
7.11 - 7.41
About Kazia Therapeutics Limited American Depositary Shares
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
Latest News
Kazia Therapeutics to Participate in J.P. Morgan Healthcare Conference Week; Clinical and Translational Update Anticipated Before Month-End
Benzinga•Jan 8
Kazia Therapeutics Achieves Initial iCR (Immune-Complete Response) in Metastatic TNBC and Delivers Q4 Business Update with Breakthroughs Across Breast Cancer, Immuno-Oncology, and GBM Regulatory Strategy
Benzinga•Nov 18
Kazia Therapeutics to Request FDA Type C Meeting to Discuss Overall Survival Data in GBM and Potential NDA Filing in Alignment with FDA initiative Project FrontRunner
Benzinga•Oct 27
Kazia Therapeutics Announces 86% Reduction in Tumor Burden in Expanded-Access Case of Metastatic TNBC Patient Treated with Paxalisib-Immunotherapy Regimen
Benzinga•Oct 2
Kazia Therapeutics Supports Australian MRFF-Funded Project Developing AI-Driven Sequential Therapy Strategy for DIPG/DMG
Benzinga•Oct 1
Leptomeningeal Metastases Market to Exhibit Growth at a Paltry CAGR of 1.9% During the Forecast Period (2025–2034) | DelveInsight
GlobeNewswire Inc.•Sep 9
S&P 500 Rises Over 1%; Citigroup Reports Upbeat Q2 Results - Benzinga
Benzinga•Jul 12
Nasdaq Surges 1%; JPMorgan Posts Upbeat Earnings - Benzinga
Benzinga•Jul 12